FLT3 tyrosine kinase as a target in acute leukemias

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Griffin, James D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; CEP 701; DNA; FLT3 LIGAND; IMATINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SEMAXANIB; SU 5614; SUNITINIB; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DNA SEQUENCE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

ACUTE DISEASE; ANIMALS; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG DESIGN; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA; MICE; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 4043184022     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200450     Document Type: Article

References (8)

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
2. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B et al. Molecular cloning of a ligand for the flt3/ flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157-1167.
3. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
4. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 917: 2434-2439.
5. Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004; 13: 169-178.
6. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2393-2398.
7. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999; 104: 659-664.
8. Shih LY, Huang CF, Wu JH, Wang PN, Lin TL, Dunn P et al. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 2004; 10: 1326-1332.